NewAmsterdam Pharma (NAMSW) Stock Price, News & Analysis

Company Overview

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Key Stats

• Today's Range: $12.21 to $12.47
• 50-Day Range: $7.96 to $14.80
• 52-Week Range: $5.52 to $16.75
• Volume: 1,800 shs
• Average Volume: 6,573 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NAMSW Stock Analysis - Frequently Asked Questions

How have NAMSW shares performed this year?

NewAmsterdam Pharma's stock was trading at $14.25 at the beginning of the year. Since then, NAMSW stock has decreased by 12.5% and is now trading at $12.4740.
View the best growth stocks for 2025 here.

Who are NewAmsterdam Pharma's major shareholders?

Top institutional investors of NewAmsterdam Pharma include Affinity Asset Advisors LLC, Wolverine Asset Management LLC and Concourse Financial Group Securities Inc..

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NAMSW
• CIK: 1936258
• Web: www.newamsterdampharma.com
• Phone: 31 35 206 2971
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $45.56 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A